Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor
- PMID: 1516631
- DOI: 10.1002/eji.1830220939
Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor
Abstract
Antigenic modulation of acetylcholine receptor (AChR) is considered to contribute to the reduction of endplate AChR in myasthenia gravis (MG). Yet, the pathogenic significance of this mechanism is unclear. To investigate the in vivo role of AChR antigenic modulation we examined the ability of bivalent F(ab')2 and monovalent Fab fragments of monoclonal antibody (mAb) 35 to passively transfer experimental autoimmune MG (EAMG) in rats. mAb 35 which binds at the main immunogenic region (MIR) of the AChR causes severe EAMG without being involved in channel function. Compared to the intact mAb, F(ab')2 35 proved to be less potent but still capable of inducing moderate EAMG, whereas Fab 35 were totally ineffective. Furthermore, both intact and F(ab')2 35 induced mild EAMG in complement-depleted rats. These results (a) provide evidence that antigenic modulation of endplate AChR is sufficient to generate passive transfer of EAMG and (b) further support the pathogenic potential of the anti-MIR antibodies in MG.
Similar articles
-
Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera.J Immunol. 1985 Apr;134(4):2343-9. J Immunol. 1985. PMID: 3973387
-
Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.J Immunol. 1996 Jul 1;157(1):386-92. J Immunol. 1996. PMID: 8683141
-
Isolation and characterization of human anti-acetylcholine receptor monoclonal antibodies from transgenic mice expressing human immunoglobulin loci.Eur J Immunol. 2005 Jun;35(6):1960-8. doi: 10.1002/eji.200526173. Eur J Immunol. 2005. PMID: 15915538
-
On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.Crit Rev Immunol. 2001;21(1-3):1-27. Crit Rev Immunol. 2001. PMID: 11642597 Review.
-
[Antibodies in myasthenia gravis].Rev Neurol (Paris). 2009 Feb;165(2):137-43. doi: 10.1016/j.neurol.2008.11.020. Epub 2009 Jan 21. Rev Neurol (Paris). 2009. PMID: 19162288 Review. French.
Cited by
-
Extraocular muscle characteristics related to myasthenia gravis susceptibility.PLoS One. 2013;8(2):e55611. doi: 10.1371/journal.pone.0055611. Epub 2013 Feb 8. PLoS One. 2013. PMID: 23409007 Free PMC article.
-
Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs.Exp Neurol. 2015 Aug;270:18-28. doi: 10.1016/j.expneurol.2015.03.010. Epub 2015 Mar 18. Exp Neurol. 2015. PMID: 25796590 Free PMC article.
-
Involvement of human muscle acetylcholine receptor alpha-subunit gene (CHRNA) in susceptibility to myasthenia gravis.Proc Natl Acad Sci U S A. 1994 May 24;91(11):4668-72. doi: 10.1073/pnas.91.11.4668. Proc Natl Acad Sci U S A. 1994. PMID: 7910962 Free PMC article.
-
Impairment Mechanisms and Intervention Approaches for Aged Human Neuromuscular Junctions.Front Mol Neurosci. 2020 Nov 16;13:568426. doi: 10.3389/fnmol.2020.568426. eCollection 2020. Front Mol Neurosci. 2020. PMID: 33328881 Free PMC article. Review.
-
Crystallization and preliminary crystallographic study of an Fab fragment of a pathogenic rat monoclonal antibody against the nicotinic acetylcholine receptor.Protein Sci. 1993 Oct;2(10):1770-2. doi: 10.1002/pro.5560021021. Protein Sci. 1993. PMID: 8251949 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical